Matches in SemOpenAlex for { <https://semopenalex.org/work/W2737698771> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2737698771 endingPage "3248" @default.
- W2737698771 startingPage "3248" @default.
- W2737698771 abstract "3248 Dasatinib (BMS-354825) is a potent inhibitor of multiple oncogenic protein kinases that has been approved by the FDA and European Union in all stages of CML and Ph+ ALL resistant or intolerant to prior therapy. On the basis of oral bioavailability, in vivo activity and pharmacokinetic profile, as well as its low toxicity, dasatinib has advanced to early-phase clinical trials for solid tumors harboring activated Src kinase. Although Src family kinases (SFK) are currently being investigated as potential targets for treatment strategies in various cancers, the effect of dasatinib on human melanoma cells has not been investigated in detail. In this study, we show that dasatinib blocks migration and invasion of human melanoma cells without affecting proliferation and survival. Moreover, dasatinib completely inhibits SFK kinase activity at low nanomolar concentrations in all 8 human melanoma cell lines examined. In addition, two known downstream targets of SFKs, focal adhesion kinase (FAK) and Crk-associated substrate (p130CAS), are inhibited with similar concentrations and kinetics. Consistent with inhibition of these signaling pathways and invasion, we show that dasatinib also down-regulates expression of matrix metalloproteinase-9 (MMP-9). We also provide evidence that dasatinib directly inhibits kinase activity of the EphA2 receptor tyrosine kinase, which is overexpressed and/or overactive in many solid tumors including melanoma. Since SFK/FAK/p130CAS as well as EphA2 signaling pathways are involved in tumor progression, our findings suggest that dasatinib is a promising agent for preventing melanoma metastasis." @default.
- W2737698771 created "2017-07-31" @default.
- W2737698771 creator A5022795218 @default.
- W2737698771 creator A5027248693 @default.
- W2737698771 creator A5044435315 @default.
- W2737698771 creator A5049796688 @default.
- W2737698771 creator A5079132331 @default.
- W2737698771 date "2007-05-01" @default.
- W2737698771 modified "2023-09-25" @default.
- W2737698771 title "The Src family kinase inhibitor dasatinib (BMS-354825) blocks migration and invasion of human melanoma cells" @default.
- W2737698771 hasPublicationYear "2007" @default.
- W2737698771 type Work @default.
- W2737698771 sameAs 2737698771 @default.
- W2737698771 citedByCount "0" @default.
- W2737698771 crossrefType "journal-article" @default.
- W2737698771 hasAuthorship W2737698771A5022795218 @default.
- W2737698771 hasAuthorship W2737698771A5027248693 @default.
- W2737698771 hasAuthorship W2737698771A5044435315 @default.
- W2737698771 hasAuthorship W2737698771A5049796688 @default.
- W2737698771 hasAuthorship W2737698771A5079132331 @default.
- W2737698771 hasConcept C108636557 @default.
- W2737698771 hasConcept C121608353 @default.
- W2737698771 hasConcept C126322002 @default.
- W2737698771 hasConcept C151166631 @default.
- W2737698771 hasConcept C184235292 @default.
- W2737698771 hasConcept C185592680 @default.
- W2737698771 hasConcept C2778820342 @default.
- W2737698771 hasConcept C2779536868 @default.
- W2737698771 hasConcept C2779976819 @default.
- W2737698771 hasConcept C42362537 @default.
- W2737698771 hasConcept C502942594 @default.
- W2737698771 hasConcept C62478195 @default.
- W2737698771 hasConcept C71924100 @default.
- W2737698771 hasConcept C86803240 @default.
- W2737698771 hasConcept C95444343 @default.
- W2737698771 hasConceptScore W2737698771C108636557 @default.
- W2737698771 hasConceptScore W2737698771C121608353 @default.
- W2737698771 hasConceptScore W2737698771C126322002 @default.
- W2737698771 hasConceptScore W2737698771C151166631 @default.
- W2737698771 hasConceptScore W2737698771C184235292 @default.
- W2737698771 hasConceptScore W2737698771C185592680 @default.
- W2737698771 hasConceptScore W2737698771C2778820342 @default.
- W2737698771 hasConceptScore W2737698771C2779536868 @default.
- W2737698771 hasConceptScore W2737698771C2779976819 @default.
- W2737698771 hasConceptScore W2737698771C42362537 @default.
- W2737698771 hasConceptScore W2737698771C502942594 @default.
- W2737698771 hasConceptScore W2737698771C62478195 @default.
- W2737698771 hasConceptScore W2737698771C71924100 @default.
- W2737698771 hasConceptScore W2737698771C86803240 @default.
- W2737698771 hasConceptScore W2737698771C95444343 @default.
- W2737698771 hasLocation W27376987711 @default.
- W2737698771 hasOpenAccess W2737698771 @default.
- W2737698771 hasPrimaryLocation W27376987711 @default.
- W2737698771 hasRelatedWork W114728680 @default.
- W2737698771 hasRelatedWork W1970105470 @default.
- W2737698771 hasRelatedWork W1972298855 @default.
- W2737698771 hasRelatedWork W1983225862 @default.
- W2737698771 hasRelatedWork W2040273766 @default.
- W2737698771 hasRelatedWork W2042132765 @default.
- W2737698771 hasRelatedWork W2103786597 @default.
- W2737698771 hasRelatedWork W2106006357 @default.
- W2737698771 hasRelatedWork W2134697926 @default.
- W2737698771 hasRelatedWork W2147545245 @default.
- W2737698771 hasRelatedWork W2242826416 @default.
- W2737698771 hasRelatedWork W2244335732 @default.
- W2737698771 hasRelatedWork W2258461888 @default.
- W2737698771 hasRelatedWork W2260146372 @default.
- W2737698771 hasRelatedWork W2397338957 @default.
- W2737698771 hasRelatedWork W2762933730 @default.
- W2737698771 hasRelatedWork W3041803442 @default.
- W2737698771 hasRelatedWork W3188342158 @default.
- W2737698771 hasRelatedWork W379616119 @default.
- W2737698771 hasRelatedWork W2897864347 @default.
- W2737698771 hasVolume "67" @default.
- W2737698771 isParatext "false" @default.
- W2737698771 isRetracted "false" @default.
- W2737698771 magId "2737698771" @default.
- W2737698771 workType "article" @default.